It would compete with Lovaza, sold by GlaxoSmithKline in the U.S. and Abbott Laboratories in Europe.
FORBES: November's Best- and Worst-Performing Biotech Stocks
Novartis, Abbott Laboratories and Boehringer Ingelheim are all thought to be pursuing hedgehog programs.
Of the new gene-targeted therapies, the one furthest along may be Xinlay from Abbott Laboratories.
Besides Diadexus, Abbott Laboratories, Roche Holding and Millennium Pharmaceuticals are pursuing new diagnostic tests.
Abbott Laboratories is spreading its wings into India, but the expansion isn't coming cheap.
Abbott Laboratories had an annual average earnings growth of 7.9% over the past 10 years.
FORBES: Yacktman Fund Buys 4 New Stocks in Q3: WLP, CHRW,LVNTA,ABR
The company is also collaborating with such companies as Abbott Laboratories, Celldex Therapeutics Inc.
The newest fat pills, Hoffmann-La Roche's Xenical and Abbott Laboratories' Meridia, are struggling after a promising start.
But even by Texas standards, the verdict against Illinois drugmaker Abbott Laboratories this June was a whopper.
Low levels can be treated with drugs, particularly versions of the B-vitamin niacin including Niaspan, from Abbott Laboratories.
Pfizer, Abbott Laboratories, and Eli Lilly all managed to notch share price increases of greater than 15%.
Elsewhere, Abbott Laboratories is working on a nicotinic drug aimed at pain relief and attention deficit hyperactivity disorder.
Other competitors in the healthcare sector include: Baxter International (BAX), Viropharma (VPHM), and Abbott Laboratories (ABT).
D. in pharmaceutics and experience at Abbott Laboratories (nyse: ABT - news - people ).
By 2010, the Meridia pill then sold by Abbott Laboratories was also yanked.
FORBES: Will The Prescription Diet Pill Market Finally Bulk Up?
Hefty operating margins, above its peers Pfizer, Abbott Laboratories, Eli Lily and Merck.
Abbott Laboratories (ABT) reports its third quarter earnings on Wednesday, October 17, 2012.
Competitors in the space include Becton Dickinson (BDX) and Abbott Laboratories (ABT).
FORBES: Meridian Bioscience Tests Well, Pays Healthy Dividends
Abbott Laboratories' Humira, for rheumatoid arthritis, psoriasis and Crohn's disease, has been one of the pharmaceutical industry's biggest success stories.
His clients in biotech, such as Bristol-Myers Squibb, Abbott Laboratories and Genentech, struggle with high failure rates and huge costs.
Medical device giant Abbott Laboratories, for example, recently announced it would jettison its laboratory-research-focused subsidiary into an entity called AbbVie.
FORBES: Why Spinoff Stocks Are Sizzling (And Should Stay Hot)
Shares in Abbott Laboratories, whose top-seller Humira has the most to lose if tofacitinib is a success, popped 2%.
Other competitors in the healthcare sector include: PDL BioPharma Inc. (PDLI), Abbott Laboratories (ABT), and Bristol Myers Squibb (BMY).
Neck stents made by Abbott Laboratories (nyse: ABT - news - people ) are coming into question, too.
Meanwhile, related companies such as Beckman Coulter rose 1.6%, while Abbott Laboratories slipped 0.1%, Bio-Rad Laboratories 2.4% and Meridian Bioscience 5.1%.
Abbott Laboratories ( ABT) has raised its dividend for 40 consecutive years, with annualized growth of 16% over the past decade.
FORBES: Three Dividend-Paying Stocks To Buy For The Long Run
For instance, Abbott Laboratories ' new drug-coated stent has taken a large share of the market in a short period of time.
Abbott Laboratories is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health.
FORBES: Yacktman Fund Buys 4 New Stocks in Q3: WLP, CHRW,LVNTA,ABR
The weekly chart of Abbott Laboratories ( ABT) shows a contracting trading range over the past two years, lines a and b.
DuPont sold to Bristol-Myers Squibb , BASF to Abbott Laboratories .
应用推荐